Cheng Fang1, Fu-Bing Wang2, Yirong Li3, Xian-Tao Zeng4. 1. Department of Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan 430071, China; Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. 2. Department of Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. 3. Department of Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. Electronic address: liyirong838@163.com. 4. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. Electronic address: zengxiantao1128@163.com.
Abstract
OBJECTIVES: The purpose of the present study was to evaluate the prognostic value of miR-199b-5p in breast cancer patients, as well as explore its effects on breast cancer cells. METHODS: The expression level of miR-199b-5p in breast cancer tissues and paired non-cancerous tissues were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Chi-square test was used to evaluate the relationship between miR-199b-5p expression and clinical parameters. Besides, overall survival analysis was carried out with Kaplan-Meier curve with log rank test, and the prognostic value of miR-199b-5p in breast cancer was evaluated by cox regression model. In addition, MTT and transwell assays in vitro were used to estimate the effects of miR-199b-5p on breast cancer cells. RESULTS: MiR-199b-5p was down-regulated in breast cancer tissues, compared with adjacent normal tissues (P<0.05). Moreover, its decreased level was significantly correlated with advanced TNM stage (P=0.008) and positive lymph node metastasis (P=0.013). Cell experiments suggested that miR-199b-5p could regulate proliferation and invasion of breast cancer cells. In addition, we found that breast cancer patients with low miR-199b-5p expression level had poorer overall survival than those with high level (log rank test, P=0.021). MiR-199b-5p was an independent prognostic factor for breast cancer patients (HR=2.318, 95%CI=1.086-4.949, P=0.030). CONCLUSION: Down-regulated miR-199b-5p in breast cancer patients is associated with malignant clinical characteristics. MiR-199b-5p may be a potential prognostic biomarker for breast cancer.
OBJECTIVES: The purpose of the present study was to evaluate the prognostic value of miR-199b-5p in breast cancerpatients, as well as explore its effects on breast cancer cells. METHODS: The expression level of miR-199b-5p in breast cancer tissues and paired non-cancerous tissues were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Chi-square test was used to evaluate the relationship between miR-199b-5p expression and clinical parameters. Besides, overall survival analysis was carried out with Kaplan-Meier curve with log rank test, and the prognostic value of miR-199b-5p in breast cancer was evaluated by cox regression model. In addition, MTT and transwell assays in vitro were used to estimate the effects of miR-199b-5p on breast cancer cells. RESULTS:MiR-199b-5p was down-regulated in breast cancer tissues, compared with adjacent normal tissues (P<0.05). Moreover, its decreased level was significantly correlated with advanced TNM stage (P=0.008) and positive lymph node metastasis (P=0.013). Cell experiments suggested that miR-199b-5p could regulate proliferation and invasion of breast cancer cells. In addition, we found that breast cancerpatients with low miR-199b-5p expression level had poorer overall survival than those with high level (log rank test, P=0.021). MiR-199b-5p was an independent prognostic factor for breast cancerpatients (HR=2.318, 95%CI=1.086-4.949, P=0.030). CONCLUSION: Down-regulated miR-199b-5p in breast cancerpatients is associated with malignant clinical characteristics. MiR-199b-5p may be a potential prognostic biomarker for breast cancer.
Authors: Luigi Fattore; Ciro Francesco Ruggiero; Maria Elena Pisanu; Domenico Liguoro; Andrea Cerri; Susan Costantini; Francesca Capone; Mario Acunzo; Giulia Romano; Giovanni Nigita; Domenico Mallardo; Concetta Ragone; Maria Vincenza Carriero; Alfredo Budillon; Gerardo Botti; Paolo Antonio Ascierto; Rita Mancini; Gennaro Ciliberto Journal: Cell Death Differ Date: 2018-09-25 Impact factor: 15.828